Targovax receives approval in Australia to conduct a

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Targovax receives approval in Australia to conduct a clinical trial with TG02 - an immunotheraphy treatment targeting RAS mutations

OSLO, Norway, June 2, 2016 (GLOBE NEWSWIRE) -- Targovax receives approval to conduct a study with TG02 and pembrolizumab, a checkpoint inhibitor, in patients with locally recurrent RAS mutated rectal cancer.

TGO2 is a cancer vaccine containing a mixture of 8 synthetic peptides representing fragments of the most common RAS mutations seen in colorectal cancer disease.

Mutations in RAS, a protein regulating cell growth, is seen in about 50% of patients with colorectal cancer and 20-30% of all cancers. It is associated with a lack of response to chemotherapy and poor prognosis. Previous and ongoing clinical studies have shown that TG peptides are able to induce RAS mutation specific immune responses. Targovax is the only research organization with RAS mutated specific vaccines at clinical development stage. This will be the first study with TG02 in humans and 20 patients will be included at Australian sites.

The study will assess safety and immune activation, both at lesional level and in peripheral blood. One cohort will only receive TG02 and another cohort will receive TG02 in combination with pembrolizumab, a PD-1 receptor inhibitor.

"We have already shown in other indications that TG peptides can induce specific immune responses and that these are associated with clinical benefits. However, this study will take us one step further in assessing immune activation at tumor level. It will also give us an indication on how our immune therapy may be enhanced when combining with a check point inhibitor" says Magnus Jaderberg, CMO at Targovax.

For further information, please contact:

Gunnar Gårdemyr, CEO Phone: +46 73 083 77 79 Email: ggardemyr@targovax.com

Øystein Soug, CFO Phone: +47 906 56 525 Email: oystein.soug@targovax.com

Arming the patient's immune system to fight cancer

Targovax is a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients. Targovax has a broad and diversified immune therapy portfolio and aims to become a world leader in its area. The company is currently developing two complementary and highly targeted approaches in immuno-oncology.

ONCOS - 102 is a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes targeting solid tumors. This treatment is designed to reactivate the immune system's capacity to recognize and attack cancer cells.

TG01 and TG02 are part of a peptide-based immunotherapy platform targeting the difficult to treat RAS mutations found in more than 85% of pancreatic cancers, 50% of colorectal cancer and 20-30% of all cancers. Targovax is working towards demonstrating that TG vaccines will prolong time to cancer progression and increase survival.

These product candidates will be developed in combination with multiple treatments, including checkpoint inhibitors in several cancer indications. Targovax also has a number of other cancer immune therapy candidates in the early stages of development.

HUG#2017396

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 72

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 117

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
Northgate’s Stanton Opening Puts Community Work First

Updated Category News Views 86

A 55,721-square-foot grocery opening can look like ordinary retail churn until you notice where the money and attention are landing. Northgate González Market’s new Stanton location arrives ahead of Thanksgiving, yes, but the more telling detail is the company’s decision to pair a major store launch with 375 jobs and more than $30,000 directed toward families,...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 61

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Great Rail Journeys Bets Bigger on Luxury Rail in 2027

Updated Category News Views 99

A $19,995 vacation is not selling a seat on a train; it is selling relief from planning, crowds and compromise. Great Rail Journeys is leaning hard into that proposition for 2027 with two additions to its premium Landmark Collection: a Europe-heavy Orient Express and Rhône cruise pairing, plus a South Africa itinerary built around safari, Victoria Falls and rail-flavored...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 44

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 25

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 78

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
Why Insurance Must Change as Family Assets Keep Growing

Updated Category News Views 32

A policy bought in the starter-home years can turn stale quietly while everything around it gets bigger, pricier and more complicated. That is the uncomfortable little truth behind Daniel C. DiCocco's discussion in HelloNation: families often treat insurance as a box checked long ago, even as they add property, savings, debt, children and fresh responsibilities. Static...

Continue Reading

Top 5 Most Recently Viewed Articles

Anticipating Earnings: Barfresh Food Group's Upcoming Report

Updated Category News Views 61

Anticipating Earnings: Barfresh Food Group's Upcoming Report Barfresh Food Group (NASDAQ: BRFH) is on the brink of releasing its quarterly earnings. Investors are keenly awaiting the announcement, scheduled for Thursday. As the date approaches, it is crucial to analyze the expectations and historical performance of the company. The consensus among analysts is that...

Continue Reading
Meta's Smart Glasses: AI Performance Lags Behind ChatGPT's

Updated Category News Views 563

Meta's AI Tools Tested Against ChatGPT Recently, Gene Munster from Deepwater Asset Management conducted a head-to-head comparison of Meta Platforms Inc.'s AI capabilities on its smart glasses and the performance of OpenAI's ChatGPT. His findings highlighted significant gaps between the two AI systems. ChatGPT Outshines Meta AI in Tests During the evaluation, Munster...

Continue Reading
Tractor Supply Company Expands Offerings with Allivet Acquisition

Updated Category News Views 79

Tractor Supply Company to Acquire Allivet Tractor Supply Company (NASDAQ: TSCO), the top retailer for rural lifestyle in the U.S., has made an exciting announcement regarding its latest acquisition. The company has signed a definitive agreement to acquire Allivet, an esteemed private online pharmacy specializing in pet and animal health. This strategic move aims to...

Continue Reading
20+ Companies Break Ground in Urticaria Treatment Innovations

Updated Category News Views 236

Overview of Urticaria Treatment Innovations Urticaria, commonly known as hives, is a skin condition characterized by raised, itchy welts that can vary in size and location. The increasing prevalence of urticaria has spurred significant growth in treatment options, with various companies leading clinical trials dedicated to developing new therapies. Factors contributing to...

Continue Reading
Alphabet's Unique AI Strategy: A Competitive Edge Over Rivals

Updated Category News Views 241

Alphabet's AI Transformation and Competitive Advantage Alphabet Inc. (NASDAQ: GOOGL), a leader in technology innovation, is transforming its approach to artificial intelligence. The company, trading at $319.08 per share and boasting a market capitalization of $3.79 trillion, is narrowing the valuation gap with notable competitors. Its advancements in Tensor Processing...

Continue Reading